Goldman Sachs Group Inc Intra Cellular Therapies, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ITCI
# of Institutions
398Shares Held
87.5MCall Options Held
309KPut Options Held
302K-
Vanguard Group Inc Valley Forge, PA9.61MShares$814 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$536 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.72MShares$315 Million1.37% of portfolio
-
Jpmorgan Chase & CO New York, NY3.44MShares$291 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$254 Million2.8% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...